Block Listing Six Monthly Return

Alliance Pharma PLC

29 June 2023

 

For immediate release

29 June 2023

                                        ALLIANCE PHARMA PLC                                        

("Alliance" or the "Company")

Block Listing Six Monthly Return

Name of applicant:		ALLIANCE PHARMA PLC
Names of schemes:		a)     The Alliance Pharma plc Approved Share Option Plan 2005 b)    The Alliance Pharma plc Share Option Plan 2006 c)     The Alliance Pharma plc Company Share Option Plan 2015 d)    The Alliance Pharma plc Long-Term Incentive Plan 2019
Period of return:	From:	28 December 2022	To:	28 June 2023
Number of securities originally admitted at date of admission:		25,000,000 ordinary shares of 1p each 28 June 2017
Balance of unallotted securities under schemes from previous return:		a)     149,637 b)    2,551,168 c)     9,572,622 d)    1,341,116
Plus:  The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for):		a)     Nil b)    Nil c)     Nil d)    Nil
Less:  Number of securities issued/allotted under schemes during period:		a)  91,715 b) 63,422 c)  0 d) 0
Equals:  Balance under schemes not yet issued/allotted at end of period:		e)     57,922 f)     2,487,746 g)    9,572,622 h)    1,341,116

Name of contact:	Chris Chrysanthou, Company Secretary
Telephone number of contact:	Tel. [phone]

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications	+ 44 (0)1249 705168
[e-mail]
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
[e-mail]
Numis Securities Limited (Nominated Adviser and Corporate Broking)	+ 44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Sher Shah
Investec Bank plc	+ 44 (0)20 7597 5970
Corporate Broking: Patrick Robb

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

END